newsfilter
← Earnings
Earnings Releases·

DBV Technologies — Third Quarter 2026 Earnings Summary

  • Reported a net loss of $64.5 million for Q3 2026 (vs. $33.2 million in Q3 2025) and $162.5 million for the first nine months (vs. $102.1 million in 2025), driven by significant increases in R&D, sales, and G&A expenses as the company scales infrastructure.
  • Management raised substantial doubt regarding the ability to continue as a going concern within the next twelve months due to insufficient cash to fund operations, with existing cash of $165.7 million expected to last only into Q3 2027.
  • Submitted the BLA for VIASKIN® Peanut Patch in children aged 4 through 7 years on September 29, 2026, requesting Priority Review, with a determination expected in Q4 2026; a BLA for the toddler program (ages 1-3) is planned for submission in 2027.
  • Refreshed the $150 million ATM program and completed a $50 million sale of ADSs to RA Capital Management, while actively evaluating additional financing alternatives including equity transactions and warrant exercises.
  • Manufacturing remediation is ongoing following an April 2026 FDA Warning Letter to contract manufacturer Fareva Amboise, with the Pre-Approval Inspection (PAI) target date scheduled after remediation completion.
Company
DBV TECHNOLOGIES SA
Sector
Healthcare
Industry
Biotechnology